Login
$COR
$356.94 +$0.00 (0.0%) After hours

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role 2025 pay Source
Robert P. Mauch Also a director
President and Chief Executive Officer
58 Since 2024
2 years
$18,256,227
Eva C. Boratto
Chief Financial Officer
Title from the Form 4 dated Nov 11, 2026
Not stated Not stated Not reported
Elizabeth S. Campbell
Executive Vice President and Chief Legal Officer
51 Since 2021
5 years
$5,176,668
Pawan Verma
EVP, Chief Data & Info Officer
Title from the Form 4 dated Nov 11, 2026
49 Not stated Not reported
Lazarus Krikorian
SVP & Chief Accounting Officer
Title from the Form 4 dated Nov 11, 2026
Not stated Not stated Not reported
Samantha L. Hammock
Executive Vice President and Chief Human Resources Officer
Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Jan 22, 2026 · updated by the 8-Ks of Aug 14, 2026 and Sep 25, 2026

Directors
11
serving now
Independent
9 of 10
stated in the proxy; 1 not stated
Average tenure
4.4 years
from year joined
CEO also chairs the board
No
D. Mark Durcan
Director Age On board Independent Committees Other public boards 2025 pay Source
D. Mark Durcan
64 2015
11 years
Independent
Executive · Chair
ASML Holding N.V. (Nasdaq: ASML) $375,217
Robert P. Mauch
59 2024
2 years
Not independent
Executive
None stated Paid as CEO
Werner Baumann
63 2023
3 years
Independent
Audit · Chair Compensation and Succession Planning Executive Special Litigation · Chair
None stated $383,095
Frank K. Clyburn
61 2024
2 years
Independent
Compliance and Risk Finance
Revolution Medicines, Inc. (Nasdaq: RVMD) $396,436
Ellen G. Cooper
61 2026
this year
Independent None stated Lincoln National Corporation (NYSE: LNC) Not stated
Lon R. Greenberg
75 2013
13 years
Independent
Compliance and Risk Executive Finance Governance, Sustainability and Corporate Responsibility · Chair
None stated $330,225
Redonda G. Miller, M.D.
59 2023
3 years
Independent
Compliance and Risk · Chair Executive Governance, Sustainability and Corporate Responsibility Special Litigation
None stated $385,225
Dennis M. Nally
73 2020
6 years
Independent
Audit Compensation and Succession Planning · Chair Executive
Morgan Stanley (NYSE: MS) $345,706
Lori J. Ryerkerk
63 2025
1 year
Independent None stated Eaton Corporation (NYSE: ETN), Norfolk Southern Corp (NYSE: NSC) $192,390
Lauren M. Tyler
64 2023
3 years
Independent
Audit Governance, Sustainability and Corporate Responsibility Special Litigation
None stated $360,940
Robert E. Sanchez Joined Oct 1, 2026
- - - - - -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

6 disclosed in the proxy filed Jan 22, 2026
Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
Amount not stated

10-year pharmaceutical distribution agreement under which we distribute branded and generic pharmaceutical products to Walgreens pharmacies (US PVA)

With Walgreens Boots Alliance, Inc. Open in proxy
Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
Amount not stated

Generics purchasing services arrangement providing access to generics and related products through a global sourcing arrangement (WBAD Arrangement)

With Walgreens Boots Alliance Development GmbH Open in proxy
Ornella Barra
Chief Operating Officer, International of WBA; director designated by WBA under the Shareholders Agreement
Amount not stated
January 2015 until May 27, 2025

Board seat designated by WBA under the Shareholders Agreement; Ms. Barra served as a director until May 27, 2025

Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
$6.275 billion in cash
June 2021

Acquisition of a majority of WBA's Alliance Healthcare businesses for cash plus two million shares of our Common Stock, subject to purchase price adjustments

With Walgreens Boots Alliance, Inc. Open in proxy
Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
Amount not stated
through 2029

Extension of the US PVA and the WBAD Arrangement by three years through 2029

With Walgreens Boots Alliance, Inc. Open in proxy
Walgreens Boots Alliance, Inc.
previously controlled more than 5% of our Common Stock
Amount not stated
through 2031

Distribution agreement to supply branded and generic pharmaceutical products to WBA's Boots pharmacies in the United Kingdom

With Walgreens Boots Alliance, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support